Role of tacrolimus prolonged release in the prevention of allograft rejection by Tan, Henkie
© 2010 Abrams et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article  
which permits unrestricted noncommercial use, provided the original work is properly cited.
Transplant Research and Risk Management 2010:2 65–70
Transplant Research and Risk Management Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
65
R E V I E W
open access to scientific and medical research
Open Access Full Text Article
12276
Role of tacrolimus prolonged release in the 
prevention of allograft rejection
Peter Abrams
Abhinav Humar
Henkie P Tan
Department of Surgery, Thomas 
E Starzl Transplantation Institute, 
University of Pittsburgh School of 
Medicine, Pennsylvania, USA
Correspondence: Henkie P Tan 
Department of Surgery, Thomas E Starzl 
Transplantation Institute, University of 
Pittsburgh School of Medicine, UPMC 
Montefiore, 7 South, 3459 Fifth Avenue, 
Pittsburgh, PA 15213, USA 
Email tanhp@upmc.edu
Abstract: Successful management of the solid-organ transplant recipient begins with prevention 
of rejection and achieving a balance between insufficient and excessive immunosuppression. 
Standard tacrolimus therapy for prevention of solid-organ transplant rejection consists of 2 divided 
doses per day. In an effort to simplify tacrolimus dosing to once daily, a new formulation (tacroli-
mus prolonged release [PR]) was chosen for its combination of a similar extent of bioavailability 
and a substantially reduced rate of clearance. Several clinical conversion studies have now been 
completed using PR to clarify its pharmacokinetics, efficacy at prevention of allograft rejection, 
and safety profiles in solid-organ transplant patients. A cohort of 67 stable kidney transplant 
recipients was converted from standard tacrolimus to PR in an open-label, multicenter study in 
the United States and Canada. A second open-label, multicenter study was performed in liver 
transplant recipients with stable graft function on standard tacrolimus therapy converted to PR. 
A third conversion study was performed as an open-label study at 5 centers in the United States 
in stable pediatric liver transplant recipients. As medication noncompliance can significantly 
contribute to the incidence of graft rejection and graft loss in transplant recipients, a potentially 
significant advance in the transplant community’s ongoing mission to optimize prevention of 
rejection occurred with the development of a once-daily tacrolimus PR. The results of these 
preliminary studies suggest that select solid-organ transplant recipients converted to PR can be 
safely maintained using the same monitoring and patient care techniques historically used for 
standard tacrolimus therapy.
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Preventing transplant organ rejection
Preventing rejection of solid-organ transplants requires steadfast commitment 
and remains a lifelong endeavor on the part of the transplant recipient and the 
transplant management team. Made possible through the use of antirejection or 
 immunosuppressive medications, the process of rejection prevention is successful only 
50% overall for various reasons including drug-resistant immune-mediated chronic 
rejection  pathways, the development of life-threatening opportunistic  infections 
or malignancy due to excessive immunosuppression, and serious adverse drug 
 reactions. In general, episodes of  rejection can be treated successfully by a growing 
 repertoire of potent  immunosuppressants. However, escalation of  immunosuppression 
to treat  rejection can induce significant patient debilitation involving significant 
neurotoxicity, electrolyte disturbances, myelosuppression, and even organ failure. 
Therefore,  successful  management of the transplant recipient fundamentally begins 
with prevention of rejection, achieving that fine balance between too little and too 
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much  immunosuppression, fully understanding the unique 
circumstances of each individual patient, and successfully 
manipulating the cellular mechanisms that facilitate or 
oppose graft tolerance.
Brief history of tacrolimus
The discovery of tacrolimus in 1984, on Mount Tsukuba 
just north of Tokyo, Japan, led to the beginning of a new 
era in solid-organ transplantation. Initially recognized as a 
potent in vitro immunosuppressive agent, tacrolimus was 
found to inhibit interleukin-2 (IL-2) production  associated 
with T-lymphocyte activation, resulting in the  suppression 
of differentiation and proliferation of  cytotoxic T cells. 
The transplant community was first made aware of the 
 immunosuppressive properties of tacrolimus by researchers 
from Japan at the 11th World Congress of the  Transplantation 
Society in Helsinki, Finland, in 1986. Further research 
regarding tacrolimus safety and efficacy was begun at the 
University of Pittsburgh. The first clinical trial of  tacrolimus 
was performed as rescue therapy for liver transplant patients 
facing  retransplantation or significant drug toxicity to treat 
ongoing severe organ rejection. The promising results in 
terms of patient and graft survival were presented at the 1990 
Congress of the  Transplantation Society in San  Francisco, 
California, USA. The first trial using tacrolimus as first-
line therapy was begun at the  University of Pittsburgh in 
the spring of 1990.1 Two  prospective, randomized trials 
conducted in the United States and Europe subsequently 
demonstrated that patient and liver graft survival were com-
parable between tacrolimus and cyclosporine; however, the 
rates of acute, steroid-resistant, and refractory rejection were 
significantly lower with tacrolimus therapy.2,3 On the basis 
of these studies, tacrolimus was clinically introduced first in 
Japan in 1993 and subsequently in the United States in 1994. 
In 2003, nearly 90% of new liver transplant recipients and 
67% of new kidney transplant recipients were discharged 
on tacrolimus-based immunosuppression.4,5
Mechanism of action
The activity of tacrolimus begins with its binding to an 
intracellular protein, FKBP-12. This initial event leads to the 
formation of a complex of tacrolimus-FKBP-12, calcium, 
calmodulin, and calcineurin, which inhibits the phosphatase 
function of calcineurin. Inhibition of calcineurin prevents the 
dephosphorylation and nuclear translocation of the nuclear 
factor of activated T-lymphocytes, both of which are critical 
events in the initiation of gene transcription for the production 
of IL-2 and other lymphokines. By blocking production of 
IL-2 and other lymphokines through calcineurin inhibition, 
tacrolimus potently suppresses T-lymphocyte activation, 
resulting in clinical immunosuppression and prevention of 
organ rejection.
Tacrolimus is rapidly absorbed in the  gastrointestinal 
tract. Peak serum concentrations of tacrolimus after 
oral administration occur in approximately 1–2 hours. 
 Tacrolimus as a compound is almost completely  metabolized 
through the cytochrome (CYP) P450 hepatic pathway before 
elimination. Additional metabolism of tacrolimus occurs by 
CYP3A4 isoenzymes and P-glycoprotein in the intestinal 
mucosa.6,7
Advances in tacrolimus dosing
Standard tacrolimus therapy (TAC) for prevention of 
 solid-organ transplant rejection consists of 2 divided doses 
per day at dosages sufficient to maintain whole-blood trough 
levels in the range of 5–15 ng/mL. In an effort to simplify 
tacrolimus dosing to once daily, a new formulation (MR-4, 
herein referred to as prolonged release [PR]) was chosen 
for its combination of a similar extent of bioavailability 
to the original version of tacrolimus and a substantially 
reduced rate of clearance. This drug profile was achieved 
through modifications of the drug capsule without altering 
the drug compound itself. PR was initially administered 
to over 100 healthy human volunteers in 5 unpublished 
phase 1  studies (3 single-dose studies in the United States 
and 2 repeat-dose studies in Europe). The PR formulation 
was reportedly well tolerated in all phase 1 studies. The 
 repeat-dose studies demonstrated that the 24-hour measured 
blood concentrations or bioavailability of PR were approxi-
mately equal to the sum of the 12-hour measured blood 
concentrations of twice-daily standard tacrolimus, suggesting 
these drug formulations were bioequivalent.8
Several clinical conversion studies have now been 
 completed using PR in an effort to clarify and  elaborate 
its pharmacokinetics (PK) in solid-organ transplant 
patients. Alloway et al9 evaluated the conversion PK of 
67 stable  kidney transplant recipients converted from 
standard  tacrolimus to PR in an open-label, multicenter, 
 single-sequence,  crossover study conducted in the United 
States and Canada with patient ages ranging from 18 to 
65 years. For 1 week, patients were administered their 
established dose of tacrolimus and  underwent routine 
drug concentration testing at the beginning and end of 
that week. These patients were then converted to the same 
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 milligram-for-milligram daily dose of PR in the morning on 
day 8. Similar drug measurements were recorded at day 8, 14, 
and 21 while taking once-daily PR. With day 8, PK data not 
included in the analysis, the measured blood concentrations 
were  comparable, supporting a 1:1 conversion of tacrolimus 
twice-daily to PR once-daily.
A second PK study of PR in transplant patients involved 
an open-label multicenter PK study in liver transplant 
 recipients with stable graft function on standard tacrolimus 
therapy converted to PR.10 The study population included 
69 patients from 10 centers in the United States with an 
age range from 18 to 65 years, who had undergone liver 
transplant at least 6 months prior to enrollment and were 
receiving stable doses of tacrolimus (.2 weeks) with a serum 
creatinine level ,2.0 mg/dL before enrollment. Patients 
were converted back and forth from standard tacrolimus to 
PR once-daily in the morning in 2-week intervals in a single 
sequence, 4-period crossover study design. Patients were 
converted to the same milligram-for-milligram daily dose of 
PR daily on days 15–28 and days 43–56. Twenty-four-hour 
PK profiles were obtained on days 14, 28, 52, and 56. The 
measured blood concentrations of tacrolimus and PR again 
indicated that at steady state, PR was relatively equivalent to 
standard tacrolimus after a milligram-for-milligram conver-
sion, this time in stable liver transplant recipients.
A third conversion study was performed as an open-label 
study at 5 centers in the United States in stable pediatric liver 
transplant recipients.11 PK, as well as safety and tolerability 
of PR, was evaluated in 18 patients #12 years of age, who 
were receiving a stable tacrolimus-based immunosuppression 
regimen for at least 2 weeks. Similar to previous studies, 
patients were converted to PR on a 1:1 (mg:mg) basis for 
their total daily dose, with serial collection of whole-blood 
samples for PK profiles. Exposure to tacrolimus at steady 
state was once again reported to be equivalent between PR 
and standard tacrolimus.
Efficacy of PR tacrolimus
In addition to PK data, these conversion studies also evalu-
ated the efficacy and long-term safety profiles of PR in com-
parison to standard tacrolimus therapy in the same patient 
cohorts. Clinical efficacy data at 2-year postconversion for 
the stable adult kidney and liver transplant recipients were 
published in 2007.12,13 Two-years postconversion follow-up 
was achieved in 59 of the original 67 kidney transplant 
patients. The mean posttransplant time period prior to PR 
therapy conversion was 3.8 years (range, 0.64–11.13 years). 
The mean tacrolimus whole-blood level ranged from 5.7 
to 7.1 ng/mL in the 2-year postconversion period. Of the 
57 kidney transplant recipients receiving mycophenolate 
mofetil (MMF) prior to study enrollment, 54 recipients 
continued on MMF therapy. Six recipients were receiving 
azathioprine (AZA) prior to enrollment, and no reported 
changes in AZA were reported during follow-up. Of the 
original 67 recipients who participated in the conversion 
study, 61 patients were taking steroids prior to enrollment, 
10 of whom required an increase in steroid dosage during 
follow-up (5 for maintenance therapy at the discretion of 
the investigator, 4 for treatment of rejection, and 1 for vas-
culitis). Steroid use was decreased in 16 recipients (15 for 
maintenance therapy at the discretion of the investigator and 
1 postrejection therapy at the discretion of the investigator). 
Patient and graft survival at 2-year postconversion were 
100% (67 of 67) and 98.5% (66 of 67), respectively, and the 
incidence of biopsy-confirmed acute rejection (BCAR) was 
6.0%. The 4 episodes of acute rejection (grade IA, IB, IIA, 
and IIB) occurred in 4  different patients at 719, 227, 155, and 
458 days, respectively, after conversion to PR. At the time of 
diagnosis of BCAR, tacrolimus levels were between 5 and 
12 ng/mL for all but 1 recipient, who had a trough level of 
3.0 ng/mL measured approximately 48 hours preceding the 
diagnosis of acute rejection.
In the conversion study involving stable adult liver 
 transplant recipients, complete follow-up data were 
achieved in 56 of 69 patients on PR treatment for 2 years. 
The mean posttransplant time interval prior to PR conver-
sion was also 3.8 years (range 0.82–12.4 years). The mean 
tacrolimus whole-blood level ranged from 6.2 to 6.6 ng/
mL over the 2-year postconversion. Prior to enrollment, 
22 patients were taking MMF, 2 patients were taking AZA, 
and 41 patients were on steroid therapy. These cotherapies 
were not altered during the 2-year postconversion period. 
The reported  incidence of BCAR at 2-year postconversion 
was 5.8%. Rejection episodes included 2 grade I rejections, 
and 1  episode each of grade II and grade III rejection 
according to standard Banff criteria. These BCAR episodes 
occurred at 190, 110, 357, and 10 days postconversion, 
respectively. All 4 episodes of BCAR were steroid treat-
ment responsive, and there were no reports of multiple 
rejections in a single patient. Patient and graft survival 
at 2-year postconversion was 98.6%. One white female 
reportedly died with a  functioning graft due to complica-
tions from squamous cell lung cancer nearly 22 months 
after conversion to PR.13
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In the pediatric liver transplant conversion study, an 
 analysis of drug efficacy at 1-year postconversion was 
 performed in all 18 patients. In this group of stable  pediatric 
liver transplant recipients, the mean posttransplant time 
 interval prior to conversion to PR was 4 years. Mean 
 whole-blood levels of tacrolimus were between 4.9 and 
5.9 ng/mL during the first 12 months postconversion to PR. 
All adjuvant immunosuppression was maintained without 
 alteration throughout the first 14 days of the study, subsequent 
to which adjustments were permitted. Of the 18 patients, 
7 patients receiving PR did not require any change in dose 
during the 1-year postconversion and 5 patients required 
only a single dose adjustment. A total of 14 patients were 
receiving adjunctive immunosuppression prior to study 
enrollment, and most patients were continued throughout 
the course of the study. It is important to note that patients 
were excluded from this study if they had experienced any 
rejection episode within 90 days prior to enrollment, any 
rejection episode within 6 months requiring antilymphocyte 
antibody therapy, or more than 2 rejection episodes within 
the last 12 months. At 1-year postconversion to PR, there 
were no cases of BCAR, discontinuation of PR therapy, and 
graft loss or death.
Most recently, a large phase 3, randomized (1:1:1), 
 open-label, 3-arm (PR/MMF, TAC/MMF, and cyclosporine 
[CsA]/MMF) noninferiority study was conducted in 60 
 centers in the United States, Canada, and Brazil, in de 
novo  kidney  transplant recipients.14 The dosing of the 3 
primary  immunosuppressants was chosen on the basis of 
 recommended ranges and was adjusted on the basis of pro-
tocol-specified target  whole-blood trough levels and accord-
ing to standard clinical  practice. Two doses of basiliximab 
induction therapy were  administered to all patients on day 
0 and between days 3 and 5. Patients were also maintained 
on corticosteroids, initiated on day 0 (500–1000 mg meth-
ylprednisolone or equivalent  intravenous bolus) followed 
by oral administration of 200 mg  methylprednisolone (or 
equivalent) on day 1 and subsequent tapering to a mean 
prednisone equivalent of 5–10 mg/d after 3 months. MMF 
(1 g twice a day) was administered according to package 
insert guidelines, and up to 1.5 g twice a day was permit-
ted in black patients. Target levels for mycophenolic acid 
were not standardized in the study protocol. Thirty of 668 
randomized patients did not receive study drug; of the 
remainder, 214 patients were randomized to PR/MMF, 
212 to TAC/MMF, and 212 to CsA/MMF. Treatment 
groups were balanced with regard to donor type and other 
baseline characteristics. Eighty-five percent of patients in 
the PR/MMF and TAC/MMF groups completed 1 year of 
 randomized treatment compared with 71% of patients in the 
CsA/MMF group.
At 1-year posttransplant, the open-label study found no 
statistical differences in the Kaplan–Meier estimates for 
patient and graft survival among all 3 treatment groups. 
Of note, no statistical significance was reported in evaluating 
the differences seen in patient and graft survival as well as 
the number and treatment of BCAR between the 2 tacrolimus 
groups in particular. The incidence of BCAR at 6 months and 
1 year was significantly lower in the TAC/MMF group than in 
the CsA/MMF group. No statistically significant differences 
were observed between the PR/MMF and CsA/MMF groups 
in terms of incidence of BCAR at 6 months and 1 year. The 
incidence of BCAR at 1 year in patients who received grafts 
from deceased donors was significantly lower (P # 0.015) in 
the PR/MMF (10/111, 9.0%) and TAC/MMF (8/106, 7.5%) 
groups than in the CsA/MMF group (21/101, 20.8%).
Safety of prolonged release 
tacrolimus
In the stable kidney transplant recipient conversion study, 
the incidence of posttransplant diabetes mellitus, hyperlipi-
demia, hypertension, infectious episodes, renal dysfunction, 
or hepatic dysfunction was similar to rates observed in 
previous studies with standard tacrolimus therapy. Serious 
adverse events reported over the 2-year postconversion 
period included cellulitis (4.5%), human polyomavirus 
(3.0%), pyelonephritis (3.0%), urinary tract infection 
(3.0%), increased serum creatinine (3.0%), and acute renal 
failure (4.5%). The clinical laboratory profile, including 
serum glucose, blood urea nitrogen, serum creatinine, 
 creatinine clearance, serum aspartate aminotransferase, 
alanine  aminotransferase, alkaline phosphatase, total 
bilirubin, and serum cholesterol, was within normal limits 
and remained stable in the 2-year postconversion period. 
Increased  isolated fasting plasma glucose ($126 mg/dL) 
was observed in 21.2% of recipients. No cases of new-onset 
insulin or oral  hypoglycemic agent use or of glycosylated 
hemoglobin $6% during the 2-year postconversion period 
were reported.
In the stable adult liver transplant conversion study, 
the safety profile of PR was consistent with that previously 
reported for standard tacrolimus therapy.15–18 Compared 
with historical rates with standard tacrolimus dosing, the 
authors found no increased risk of infection, renal dysfunc-
tion, hepatic dysfunction, posttransplant diabetes mellitus, 
hyperlipidemia, or hypertension in the postconversion 
Transplant Research and Risk Management 2010:2 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
69
Role of tacrolimus
period. Serious adverse events included pyrexia (5.8%), 
incisional hernia (5.8%), cholangitis (2.9%), cholestasis 
(2.9%), diarrhea (2.9%), influenza (2.9%), and pneumonia 
(2.9%). There were no significant differences between liver 
transplant recipients who were receiving MMF and/or AZA 
cotherapy and those who were not in terms of the 2-year 
incidence of renal, hepatic, or lipid-related adverse events, 
hypertension, gastroenteritis, gastrointestinal disturbances, 
or glucose abnormalities. This was also true of patients 
taking steroid cotherapy compared with those patients on 
steroid-free regimens. However, significantly (P = 0.0179) 
more patients who took prednisone demonstrated glucose 
abnormalities than those who did not. Approximately, 
23% of patients had new-onset fasting plasma glucose 
levels $126 mg/dL during the 2 years after conversion. 
A reported 4.7% of patients had new-onset requirement for 
insulin, whereas 4.7% had new-onset requirement for an oral 
hypoglycemic medication.
In the pediatric liver transplant conversion study, safety 
of PR was assessed on the basis of adverse events, and the 
results of routine clinical laboratory tests and vital sign 
measurements were collected according to protocol. The 
postconversion safety profile of PR in the pediatric liver 
transplant study was similar to the well-established profile 
for patients maintained on standard tacrolimus therapy. 
No new cases of diabetes mellitus or glucose metabolism 
disorder were reported. There was no reported trend to 
suggest an increase in the incidence of adverse events over 
the duration of PR therapy. No de novo malignancies were 
detected during the 1-year postconversion follow-up in this 
patient population.
In the de novo kidney transplant study, the safety 
profile of PR/MMF in comparison with CsA/MMF was 
similar to the observed TAC/MMF profile and consistent 
with  previously reported profiles of TAC in comparison 
with CsA. There were no significant differences in rates 
of bacterial, fungal, or viral infections between treatment 
groups. Consistent with  previous reports, the incidence of 
new-onset oral  hypoglycemic agent use was significantly 
higher in both tacrolimus groups compared with the CsA/
MMF group. However, the incidence of new-onset use of 
insulin $30 days was not significantly different between 
treatment groups.
Conclusions
As medication noncompliance can be a significant variable 
contributing to the incidence of graft rejection and graft loss 
in transplant recipients, a potentially significant advance in 
the transplant community’s ongoing mission to optimize 
prevention of rejection occurred with the  development of 
a once-daily tacrolimus PR. Although there is no direct 
 evidence that the use of PR may improve compliance 
in  comparison to TAC, keeping in mind the reasons for 
 antirejection medication noncompliance are complex, it 
is well established that reducing the dosing frequency of 
medications can be a significant contributor to improving 
compliance.19,20 The results of these preliminary studies sug-
gest that select solid-organ transplant recipients converted 
to PR can be safely maintained using the same therapeutic 
monitoring and patient care techniques historically used for 
standard tacrolimus.
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